Paul Conyngham designed an mRNA vaccine treatment plan for a dog with cancer, using AI tools including ChatGPT to assist the process. Sam Altman shared the story, and it went viral.
Many treat it as yet another proof that "AI is changing medicine." But I want to discuss it from another angle — it touches a fundamental tension in AI applications: where is the boundary between innovation and regulation?
---
A Special Case
First, understand what makes this case unusual.
Paul Conyngham didn't just open ChatGPT and ask "how do I cure cancer." He has a biology background, understands mRNA vaccine principles, and can evaluate whether AI's suggestions are reasonable.
More importantly, the patient was a dog.
Why does that matter? Because human medical experiments require strict ethical review and regulatory approval. Pet medicine is far more relaxed: with the owner's consent, a veterinarian can try experimental treatments.
This creates a unique space:
- Complex enough to require real scientific knowledge and skill
- Lightly regulated, allowing rapid iteration and experimentation
- Manageable ethical risk, since it involves pets, not humans
- High emotional value — owners are willing to try unconventional options
- Genomic sequencing and bioinformatics analysis
- Protein structure prediction
- Immunogenicity assessment
- Drug delivery system design
- Help understand complex biology literature
- Generate and evaluate different design options
- Check logical consistency and flag potential problems
- Safety: AI-generated plans may contain flaws even experts can't easily spot; small errors in medicine can be serious.
- Ethics: loose pet regulation doesn't excuse ignoring animal welfare.
- Legal: if AI-assisted treatment goes wrong, who bears liability — the vet, the AI provider, or the owner?
This space is exactly where AI can play an enormous role.
---
Why This Matters
mRNA vaccine technology is one of the biggest biomedical breakthroughs of recent years. COVID-19 vaccines showed the world its power — but those were mass-produced, one-virus products.
Personalized cancer vaccines are a completely different concept. Every cancer patient's tumor is unique, with its own combination of mutations. A personalized mRNA vaccine must be designed per patient: sequence the tumor's genome, identify unique mutations, and design a targeted vaccine.
This is an extremely complex process involving:
Traditional pipelines require enormous expert effort and time. AI is changing that.
---
AI's Role
According to Paul Conyngham, he used ChatGPT and similar tools to:
The key point: AI is not replacing the expert — it is augmenting the expert. Paul remained the decision-maker, evaluating AI's suggestions and bearing responsibility for the treatment. AI is like an extraordinarily knowledgeable research assistant that retrieves information, drafts plans, and points out pitfalls instantly.
This "human expert + AI assistance" model may become the standard workflow in many professional fields.
---
A Deeper Meaning: A Regulatory Testing Ground
Sam Altman shared the story not just because it was touching. It raises a bigger question: how do you drive innovation in heavily regulated domains?
Bringing a new human drug to market typically takes 10+ years and billions of dollars. Regulation protects patients but also slows innovation. Pet medicine creates a unique sandbox: faster innovation, lower cost of failure, and lessons that can inform human medicine.
If an AI-designed mRNA vaccine works in dogs, the odds of success in humans rise substantially — like validating in a staging environment before deploying to production.
---
A Parallel: Open-Source Robotics
In the same day's AI news, Unitree open-sourced its whole-body teleoperation dataset, and AI2 released MolmoBot, a robot arm trained entirely in simulation. Together these lower the barrier for small teams to do serious robotics research.
The common thread with personalized medicine: high-risk, high-complexity physical-world interaction. In the virtual world, mistakes are cheap to roll back. In the physical world, an error can break a robot or harm a patient. That's why open datasets and simulation training matter — validate thousands of times in simulation before touching reality.
Medicine follows the same logic: cell experiments, small animals, large animals, then human trials. If data from pet treatments can accelerate this pipeline, the whole industry benefits.
---
Risks and Ethics
---
Implications
For technologists: AI's application boundary keeps expanding — from text to code to medicine. But AI won't replace human experts, at least not soon. It's more likely to become a super-tool letting one person do what once took a team.
For regulators: The story shows regulatory complexity. Too strict kills innovation; too loose invites risk. Phased regulation — allowing more experimentation in low-risk settings like pet medicine, then scaling to high-risk settings — may be one path.
For everyone: AI is lowering the barrier to expert knowledge. That doesn't mean replacing doctors — experience, judgment, and human care still matter — but it lets us better understand our health and communicate with professionals.
---
Final Thoughts
Paul Conyngham's story moves us not just because of cool technology, but because of a deeper human emotion: facing illness and death, we will try anything to save a life we love.
How did the dog's treatment turn out? We don't know yet. But regardless of outcome, the attempt itself is meaningful. It shows AI's boundaries are far wider than we imagined — it can help save lives, not just write poems and code.
The road is full of challenges and risks. But those challenges make every step of exploration precious.
After all, isn't technology's ultimate purpose to make the world better?